Pharvaris BV (PHVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Pharvaris BV (PHVS) Competitors
The companies most similar to Pharvaris BV are Pharming Group NV (PHAR), Palvella Therapeutics (PVLA) and Vera Therapeutics (VERA). By market cap, Pharvaris BV ranks 4th of the 13 companies on this page; Travere Therapeutics (TVTX) is the largest at $4.86B. The median P/E of the 3 companies with a P/E is 39.3x.
Peer Comparison
PHVS's revenue growth of 0.0% is below the peer median of 11.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Pharvaris BV (PHVS) | $2.36B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Palvella Therapeutics, Inc (PVLA) | $2.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Biohaven Ltd. (BHVN) | $2.09B | N/A | N/A | 0.0% | -315.9% | 0.0% | 0.00% |
| Vericel Corp Ord (VCEL) | $2.91B | 89.8x | 9.1x | 10.3% | N/A | 26.5% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Maravai Lifesciences Holdings Inc (MRVI) | $1.96B | N/A | 5.2x | -30.8% | -28.3% | 10.1% | 0.00% |
| Travere Therapeutics Inc (TVTX) | $4.86B | N/A | 7.2x | -18.7% | -23.1% | 36.2% | 0.00% |
| Vir Biotechnology Inc (VIR) | $1.71B | N/A | 5.4x | -61.0% | N/A | 19582.0% | 0.00% |
| Peer median | $2.01B | 39.3x | 6.3x | 0.0% | -35.0% | 11.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to Pharvaris BV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| Palvella Therapeutics, Inc (PVLA) | Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from... | PVLA competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Uniqure NV (QURE) | uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. | QURE competitors |
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Biohaven Ltd. (BHVN) | Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders... | BHVN competitors |
| Vericel Corp Ord (VCEL) | Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures... | VCEL competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Maravai Lifesciences Holdings Inc (MRVI) | Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines... | MRVI competitors |
| Travere Therapeutics Inc (TVTX) | Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification... | TVTX competitors |
| Vir Biotechnology Inc (VIR) | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. | VIR competitors |
Frequently Asked Questions About PHVS
Who are Pharvaris BV's main competitors?
The companies most similar to Pharvaris BV include Pharming Group NV (PHAR), Palvella Therapeutics (PVLA), Vera Therapeutics (VERA), Uniqure NV (QURE) and Viridian Therapeutics (VRDN), listed from the closest match.
Who is Pharvaris BV's biggest competitor?
Travere Therapeutics (TVTX) is the largest of the similar companies at $4.86B; Pharming Group NV (PHAR) is the closest match by business profile, size, sector and industry.
How does PHVS stock compare with its competitors?
PHVS' net margin is 0.0% against a peer median of 0.0%.
Which of Pharvaris BV's competitors pays a higher dividend?
Pharvaris BV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Pharvaris BV bigger than its competitors?
No. Pharvaris BV is 4th by market cap among the 13 companies on this page; the largest is Travere Therapeutics (TVTX) at $4.86B.
PHVS pages: Overview, Financials, Competitors